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OBJECTIVES The purpose of this study was twofold: to assess whether biatrial pacing is superior to
single-site pacing and capable of reducing the frequency of episodes of paroxysmal atrial
fibrillation (PAF); and to compare pacing of the proximal coronary sinus (PCS) with the
distal coronary sinus (DCS) and the effects of sequential or simultaneous biatrial pacing.
BACKGROUND Interatrial conduction abnormalities have a role in the initiation of PAF. Biatrial pacing
alters the site and timing of atrial depolarization and may benefit those with drug-
resistant PAF.
METHODS Nineteen patients with PAF who were intolerant of or refractory to medication were studied.
All received right atrial (RA) and coronary sinus (CS) leads (either PCS or DCS). For three
months the pacemaker was set in sensing mode only. Subsequently each patient completed
three-month periods in random order in the following modes: RA pacing, CS pacing, biatrial
pacing using inter-atrial delays of 15 and 70 ms.
RESULTS Sixteen patients received a benefit from one or more pacing modes. The greatest reduction in
PAF episodes was seen during biatrial pacing, especially with leads sited at the high right
atrium (HRA) and distal CS (p  0.0048). There was no difference for sequential or
simultaneous pacing. Three patients derived no benefit.
CONCLUSIONS In selected patients, biatrial pacing causes a significant decrease in atrial fibrillation episodes.
Optimal lead sites were at the HRA and DCS. Simultaneous pacing conferred no benefit over
sequential pacing. (J Am Coll Cardiol 2002;40:457–63) © 2002 by the American College
of Cardiology Foundation
Atrial fibrillation (AF) is the most common clinically
encountered arrhythmia in the adult population (1–4). Up
to 60% of the cases presenting with AF may do so in the
paroxysmal form of this arrhythmia (2). Pharmacological
control is the first line of therapy, but AF may be associated
with low success rates, high recurrence rates, or patient
intolerance. There is therefore considerable interest in
non-pharmacological therapy in the maintenance of sinus
rhythm (5).
A variety of abnormalities of atrial electrophysiology are
found in patients susceptible to AF (6–12). Inter-atrial
conduction block in particular results in delayed activation
of the atria, and such patients have a high incidence of atrial
tachyarrhythmias (13). Other triggers for paroxysmal atrial
fibrillation (PAF) include atrial premature complexes and
sinus bradycardia (14). In patients with sinus bradycardia,
atrial pacing has been observed to prevent PAF (15),
presumably in part because of correction of rate. Special
algorithms have also been proposed for suppression of
pauses or atrial premature beats, which may be triggers for
AF (16).
Biatrial pacing has been used in patients with and without
bradycardia or organic heart disease (17). It is aimed at
restoring inter-atrial synchrony, based on the hypothesis
that patients with refractory PAF have increased inter-atrial
conduction times, predisposing them to their arrhythmia
(18). Although there is some information on proximal
coronary sinus (PCS) pacing (19), there is little information
on distal coronary sinus (DCS) pacing or the effect of
varying right to left inter-atrial pacing intervals on the
incidence of AF.
The aim of the present study has been to assess whether
biatrial pacing is superior to single-site pacing, capable of
reducing the frequency of clinical episodes of PAF in
patients without underlying sinus bradycardia or sinus
pauses. It compares pacing of the PCS with pacing of the
DCS and compares the effects of sequential with simulta-
neous biatrial pacing on the suppression of clinically symp-
tomatic episodes of PAF.
METHODS
Patients. We recruited 19 patients with recurrent PAF
who were refractory to, or unable to, tolerate two or more
antiarrhythmic drugs. Patients with evidence of sinus node
disease were specifically excluded. The study was approved
by the Maidstone NHS Trust Ethics Committee, and all
patients gave written, informed consent. All patients were
reliable witnesses to their symptoms of palpitations, which
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correlated entirely with episodes of AF in more than 192 h
of Holter monitoring (i.e., 4  48 h of continuous electro-
cardiograph recordings) per patient.
The study population involved 19 patients consisting of
nine male and 10 female patients with a mean age of 62
years. Analysis of their concurrent medical history showed
that seven had coexistent hypertension, one with ischemic
heart disease and four with thyroid disease secondary to
previous amiodarone use. All except one patient had normal
left ventricular function. Table 1 summarizes the patients
and their details, including current and previous drug
therapy. Patient number does not refer to the order of
implantation.
Study methodology. All patients underwent echocardiog-
raphy and assessment of sinus node function by Holter
monitoring and exercise testing. Patients with sinus node
dysfunction were excluded. The monthly count of PAF
episodes was taken from a three-month period, and the
mean value was calculated. Duration of the PAF episodes
had to be 1 min, although usually episodes lasted up to
several hours prior to pacing.
Pacing methodology. Each patient underwent implanta-
tion of two permanent pacing leads, a right atrial (RA)
active fixation lead (CPI sweet tip model 4269) and a
coronary sinus (CS) Medtronic 2188 lead. The RA lead was
sited in either the high right atrium (HRA) close to the
sinus node or RA appendage (RAA). The CS lead was sited
in either the PCS (i.e., 0 to 35 mm from coronary os) as
observed on fluoroscopy or the DCS (35 to 60 mm from
coronary os) as observed on fluoroscopy. Optimal threshold
and lead stability was obtained by standard manipulation of
the pre-formed CS lead tip. The permanent lead positions
are illustrated in Figures 1 and 2.
The position of the leads was assigned randomly to each
Abbreviations and Acronyms
AF  atrial fibrillation
CS  coronary sinus
DCS  distal coronary sinus
HRA  high right atrium
PAF  paroxysmal atrial fibrillation
PCS  proximal coronary sinus
RA  right atrial/atrium
RAA  right atrial appendage
Table 1. Patient Characteristics
Patient Gender Age
LA Size
(cms)
LV
Function Comorbidity
RA Pacing
Site
Mean AF Episodes
Per Month
Current
AAD
Previous
AAD
Proximal coronary sinus site
1 F 72 3 n nil RAA 15 dx a,f,b,v
2 F 77 3.8 n HT HRA 30 s a,f,b
3 M 70 4 n HT HRA 4 a,dx f,s
4 M 72 3.3 r IHD, Thyr HRA 30 nil a,s,f
5 F 68 3 n Thyr HRA 6 v,dx a,s,f
6 F 52 3.9 n HT RAA 4 nil d,f,s
7 F 68 3.3 n nil HRA 2 nil a,s,f,v
8 F 58 3.4 n HT RAA 30 p,dx a,s,f
Distal coronary sinus site
9 M 55 4.4 n nil HRA 8 f a,s
10 M 58 3.6 n HT,Thyr RAA 30 f a,s
11 M 54 2.8 n nil RAA 9 nil a,s,f
12 F 61 2.8 n Thyr HRA 30 p,dx d,f,
13 M 52 3 n nil RAA 8 s d,f,
14 M 67 3.5 n nil HRA 30 nil a,s,f
15 F 57 2.5 n HT HRA 4 f,dx a,s
16 F 66 3.4 n nil RAA 30 f b,v,s
17 M 50 3.1 n nil HRA 10 s f,b
18 M 65 3 n nil RAA 8 a,dx a,f,s,b
19 F 70 3.7 n HT HRA 15 nil a,f,s,b
a amiodarone; AAD antiarrhythmic drug therapy; b beta blocker; d disopyramide; dx digoxin; f flecainide; HRA high right atrium; HT hypertension; IHD
ischemic heart disease; LA  left atrium; LV  left ventricle; n  normal LV function; p  propafenone; r  reduced LV function; RA  right atrial; RAA  right atrial
appendage; s  sotalol; Thyr  hypothyroidism due to previous amiodarone; v  verapamil.
Figure 1. Chest radiograph showing biatrial pacemaker in situ with PCS
lead.
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patient using Greco-Latin Squares. Pacing was done via a
Medtronic Thera DR pacemaker. The right atrium (RA)
lead was inserted in the “atrial” port of the generator, and
the CS lead into the “ventricular” port. Inter-atrial pacing
delays, sensed from the RA lead position (i.e., HRA or
RAA), were 70 ms for sequential biatrial pacing and 16 ms
for simultaneous biatrial pacing. The latter delay was
programmed into the Thera DR pacemaker by software
customized by Medtronic Inc.
Table 2 summarizes the four anatomical lead combina-
tions and the number of patients in each group.
Study design. The recurrence of PAF was evaluated before
and after pacing by means of patient symptom diaries
because the pacemaker Holter function had to be sacrificed
for the customized software. For three months the pace-
maker was set in sensing mode only, each patient acting as
his or her own control during this period. Subsequently,
each patient completed four three-month periods in each of
the following modes in random order:
three months of single-site pacing from the RA site
(HRA or RAA), i.e., pacing “R”AAI mode at 70
beats/min.
three months of CS pacing (PCS or DCS) (i.e., “L”AAI
mode at 70 beats/min).
three months of biatrial pacing using an inter-atrial delay
of 70 ms at 70 beats/min base rate.
three months of biatrial pacing using a 16-ms inter-atrial
delay at 70 beats/min base rate.
A delay of 70 ms was chosen because this would be the
interval between the sinus node and CS region in a normal
heart assuming a conduction velocity in the atrium of
approximately 0.6 mm/ms (20).
Thus, after pacemaker implantation there were 15
months of monitoring for each patient, during which the
recurrence of PAF was evaluated using patient documenta-
tion diaries, and 48-h Holter monitoring was undertaken on
three occasions in each three-month period. All antiar-
rhythmic drugs and antithrombotic therapy remained unal-
tered throughout the study, so that any observed clinical
change could be potentially attributable to the pacing
therapy rather than the changes in the pharmacological
therapy.
Statistical analysis. The paired Student t test with two-
tailed distribution was used to evaluate statistical signifi-
cance of the results.
RESULTS
There was no correlation with any of the baseline clinical
variables and efficacy of AF prevention. Drug therapy was
unaltered during the study and was unrelated to patient
outcome. There was one case of lead displacement that
occurred from the PCS position within 24 h of placement
(Patient 3). The Medtronic 2188 lead was repositioned in
the CS os with no further displacement or complication.
There were no other acute or chronic adverse events. None
of the patients developed sustained AF. There was no
increase in episodes per month for any patient in any pacing
mode. Results are summarized in Tables 3 and 4 and
illustrated in Figures 3 and 4.
Effect of lead position on PAF. The effects of single-site
atrial pacing are summarized in Table 3. The effects of
dual-site atrial pacing, both sequential and simultaneous,
are summarized in Table 4. Only three patients (Patients 2,
8, 10) derived no benefit from any of the pacing modalities.
Those patients with no benefit from a pacing modality had
no significant difference in the number or duration of their
episodes of PAF, and none developed sustained AF. The
alteration in duration of episodes was relevant only for those
patients deriving benefit, but not total suppression of AF,
from their pacing modalities.
EFFECT OF RA ATRIAL PACING. Right atrial pacing alone at
70 beats/min, whether from the HRA or the RAA, led to a
reduction in the mean number of symptomatic episodes per
month of PAF in 12 patients. In seven patients there was no
change in the number or duration of episodes. The overall
mean reduction was 6.37 episodes per month (p  0.0031)
with a standard deviation of 8.13. Pacing from the RAA at
70 beats/min versus pacing from the HRA at 70 beats/min
showed benefit from both sites. Statistical significance
(Student t test) is shown in Table 3, which shows that the
reduction is highly significant overall, with the greatest
reduction in AF episodes obtained from pacing the RAA.
Table 2. Anatomic Combinations of Site of Endocardial Pacing
Leads
HRA RAA Total
PCS 5 3 8
DCS 6 5 11
DCS  distal coronary sinus; HRA  high right atrium; PCS  proximal coronary
sinus; RAA  right atrial appendage.
Figure 2. Chest radiograph showing biatrial pacemaker in situ with DCS
lead.
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EFFECT OF CS SINGLE-SITE PACING. Pacing from the CS
alone at 70 beats/min benefited 13 of 19 patients. In six
patients there was no change in their symptoms. The
statistical analysis (Student t test) shows that the reduction
in symptoms from pacing CS sites is highly significant when
compared with the pre-pacing control state. A greater
percentage derived benefit from distal than from PCS
pacing (p  0.05).
Effect of biatrial sequential (70-ms interval) pacing. Fif-
teen of nineteen patients obtained symptomatic benefit
(Table 4). The mean reduction was 8.58 episodes per month
with a standard deviation of 9.22. Statistical analysis (Table
4) shows this effect to be highly significant (p  0.000738).
EFFECT OF PACING RA AND PCS. Biatrial pacing including
the PCS site benefited six of eight patients (see Table 4).
The mean reduction in symptoms was 7.38 episodes per
month (p  0.084).
EFFECT OF PACING RA AND DCS. Biatrial pacing including
the DCS benefited nine of 11 patients (Table 4). The
average reduction in symptoms was 8.71 episodes per month
with a standard deviation of 8.71 (p  0.0048).
Biatrial simultaneous (16-ms interval) pacing. Fifteen of
19 patients benefited from biatrial pacing with 16-ms
inter-atrial pacing delay, including PCS and DCS positions
(Table 4). The mean reduction of symptoms was 8.74
episodes per month (p  0.0007) with a standard deviation
of 9.43.
Six of the eight patients paced from the PCS had a
reduction in the frequency of symptoms. The mean reduc-
tion in symptoms was 7.38 episodes per month (p 
0.0834) with a standard deviation of 10.34.
Nine of the 11 patients derived benefit from DCS pacing.
The mean reduction in symptoms was 9.73 episodes per
month. Statistical analysis (Table 4) shows the reduction in
symptoms with biatrial pacing with a 16-ms inter-atrial
delay to be statistically significant when proximal and distal
coronary sinus positions are compared together (p 
0.0007). Pacing from the DCS is also statistically significant
(p  0.0053). Although six of the eight patients who
underwent biatrial pacing via the PCS with a short inter-
atrial delay benefited from this program, the magnitude of
the changes did not reach statistical significance (p  0.08).
Examination of the change in episodes of AF showed the
reduction in symptoms by pacing the DCS to be statistically
significant (i.e., p  0.05) whether pacing was carried out
from the DCS alone or as part of biatrial pacing at 70 and
16 ms inter-atrial delay.
Although PCS pacing led to an improvement in symp-
toms in five of eight patients for single-site pacing, and in
six of eight patients with biatrial pacing, the reduction in
symptoms by PCS pacing either alone or biatrially at 70 ms
or 16 ms did not reach statistical significance as p  0.05.
All these changes are illustrated in Figures 3 and 4.
Role of inter-atrial conduction delay. Although inter-
atrial conduction time was not a criterion for entry into the
Table 3. Single Site Pacing
Site
Number of
Patients
Patients
Free of
Symptoms
Patients
Deriving
Benefit
Patients
Deriving
No Benefit Mean Reduction
in AF Episodes
per Month
Standard
Deviation p Value
Reduction in
Duration of PAF
Episodes (h)n % n % n %
RAA 8 1 12.50 4 50.00 3 37.50 9.13 10.95 0.05 6.56
HRA 11 2 18.18 5 45.45 4 36.36 4.36 4.97 0.015 5.25
PCS 8 3 37.50 2 25.00 3 37.50 6.38 9.41 0.096 3.02
DCS 11 3 27.27 5 45.45 3 27.27 6.00 6.78 0.007 6.5
All RA 19 3 15.79 9 47.37 7 36.84 6.37 8.13 0.003 5.8
All CS 19 6 31.58 7 36.84 6 31.58 6.63 7.75 0.015 5.03
AF  atrial fibrillation; CS  coronary sinus; DCS  distal coronary sinus; HRA  high right atrium; PAF  paroxysmal atrial fibrillation; PCS  proximal coronary sinus;
RA  right atrium; RAA  right atrial appendage.
Table 4. Biatrial Pacing
Site
Number of
Patients
Patients
Free of
Symptoms
Patients
Deriving
Benefit
Patients
Deriving
No Benefit Mean Reduction
in AF Episodes
per Month
Standard
Deviation p Value
Reduction in
Duration of PAF
Episodes (h)n % n % n %
PCS 70 ms 8 5 62.50 1 12.50 2 25.00 7.38 10.35 0.084 2.31
PCS 16 ms 8 4 50.00 2 25.00 2 25.00 7.38 10.34 0.083 2.28
DCS 70 ms 11 2 18.18 7 63.64 2 18.18 9.45 8.71 0.005 2.8
DCS 16 ms 11 3 27.27 6 54.55 2 18.18 9.73 9.10 0.005 2.5
All BiA 70 ms 19 7 36.84 8 42.11 4 21.05 8.58 9.22 0.0007 2.59
All BiA 16 ms 19 7 36.84 8 42.11 4 21.05 8.74 9.43 0.0007 2.57
AF  atrial fibrillation; All BiA 16 ms  biatrial paced with interatrial delay of 16 milliseconds; All BiA 70 ms  biatrial paced with interatrial delay of 70 milliseconds; DCS
16 ms  biatrial pacing with distal coronary sinus lead and delay of 16 milliseconds; DCS 70 ms  biatrial pacing with distal coronary sinus lead and delay of 70 milliseconds;
PAF  paroxysmal atrial fibrillation; PCS 16 ms  biatrial pacing with proximal coronary sinus lead and delay of 16 milliseconds; PCS 70 ms  biatrial pacing with proximal
coronary sinus lead and delay of 70 milliseconds.
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study, 16 of 19 patients had a prolonged inter-atrial con-
duction time (100 ms in sinus rhythm). Three patients
(Patients 2, 8, 10) had normal inter-atrial conduction times
in sinus rhythm. It is these patients who had no benefit form
any of the above pacing modalities.
DISCUSSION
The mechanism of AF involves multiple random waves of
reentrant electrical circuits moving from one area of atrial
muscle to another (21). This is thought to occur on the basis
of an abnormal atrial substrate in which inter-atrial conduc-
tion delays, short atrial refractory periods with increase in
dispersion, and various triggering foci assist in the setting up
and sustaining of such circuits. A combination of delayed
intra- and inter-atrial conduction and heterogeneous refrac-
toriness and recovery of excitability may contribute to the
abnormal atrial substrate necessary to sustain the multiple
reentrant wavelets leading to AF. Atrial ectopic beats with
irregular coupling intervals may further alter the electro-
Figure 3. Graph showing mean number of atrial fibrillation (AF) episodes per month for different pacing modes. BiA 16  simultaneous biatrial pacing
(16-ms delay); BiA 70  sequential biatrial pacing (70-ms delay); CS  coronary sinus pacing; RA  right atrial pacing.
Figure 4. Graph showing mean number of atrial fibrillation (AF) episodes per month by pacing subgroup. BiA 16  simultaneous biatrial pacing (16-ms
delay); BiA 70  sequential biatrial pacing (70-ms delay); BIA(D)16  simultaneous biatrial pacing with a DCS lead; BIA(D)70  sequential biatrial
pacing with a DCS lead; BIA(P)16 simultaneous biatrial pacing with a PCS lead; BIA(P)70 sequential biatrial pacing with a PCS lead; CS coronary
sinus pacing; DCS distal coronary sinus pacing; HRA high right atrial pacing; PCS proximal coronary sinus pacing; RA right atrial pacing; RAA
 right atrial appendage pacing.
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physiological properties and trigger AF. The development
of AF leads to electrophysiological, mechanical, and cellular
changes that perpetuate AF (6–12).
It has also been shown that a focal trigger can be
responsible for the initiation of AF. Electrophysiological
studies have shown the foci to be in the pulmonary veins in
up to 90% of patients with AF. Pulmonary venous sites have
also been shown to be the commonest site of origin of “focal
AF,” characterized by extrasystoles, irregular atrial tachycar-
dia, and AF due to the same focus firing irregularly at
different rates (22–24).
Effect of pacing on AF triggers. Atrial pacing may sup-
press PAF by different mechanisms. First, atrial pacing can
suppress atrial ectopics or remove pauses, which can be the
trigger for paroxysms. The importance of atrial-based pac-
ing in preventing AF has been observed in patients with sick
sinus syndrome. A variety of mechanisms have been pro-
posed by which atrial pacing may modulate the initiating
mechanisms and reduce the frequency of PAF in these
patients. These include the elimination of significant pauses
by either atrial pacing at the conventional fixed rate, constant
higher rate pacing for overdrive suppression, or physiological
AAIR pacing to achieve constant overdriving (16).
In a large number of retrospective studies on patients with
sick sinus syndrome, significant reduction of AF recurrences
with atrial pacing compared with ventricular pacing has
been documented. Whether this was because of the proar-
rhythmic effect of ventricular pacing or the beneficial effect
of atrial pacing is unclear (25–27). The dual site atrial
pacing to prevent atrial fibrillation (DAPPAF) study (28)
compared dual-site atrial pacing, single-site atrial pacing,
and support pacing modalities for the prevention of AF.
Patients included had episodes of PAF and a bradyarrhyth-
mia in need of pacing. Echo analysis suggests that DDDR
pacing may be detrimental to ventricular function and that
AAIR pacing may be more effective.
However, our patient group specifically excluded patients
with sinus node dysfunction, 16 of whom derived benefit
from one or more pacing modalities. Other workers have
shown the benefit of atrial pacing in patients with non-
bradycardia-dependent PAF in the absence of sinus node
disease (11,18,19). Thus, our single-site pacing at 70 beats/
min may be beneficial because of the above-mentioned “rate
smoothing” mechanisms. Levy et al. (29) also observed this
phenomenon.
Effect of biatrial pacing on atrial substrate. Early studies
by Daubert et al. (17) in patients with advanced inter-atrial
conduction block showed that pacing simultaneously from
the HRA and CS is associated with reduced AF recur-
rences. This is attributed to atrial resynchronization and
alleviation of inter-atrial block. Dislodgment of the CS lead
in 20% of the patients was the biggest limitation in this
mode of pacing and appears to have been overcome, as we
have shown, by the use of specifically designed leads such as
the Medtronic 2188 lead used in the present study.
Saksena et al. (30) and Prakash et al. (31) evaluated the
role of dual-site RA pacing in patients with drug-refractory
AF. They demonstrated that dual-site RA pacing
(HRA/CS os) resulted in an increase in AF-free interval
and a reduction in the need for antiarrhythmic therapy. At
one year approximately 80% of patients were free of frequent
or chronic AF. Other studies have shown biatrial pacing to
reduce the frequency of PAF episodes in patients either with or
without surface P-wave prolongation (17,32,33).
Our study examines the role of single-site and biatrial
pacing in the suppression of PAF in patients with frequent
episodes of AF (mean 15.9 episodes per month) who had no
underlying bradycardia. Although the study group was
comparatively small (19 patients), all acted as their own
controls to extensively evaluate the role of single-site RA
pacing, single-site CS pacing, biatrial pacing (RA  CS),
and finally, the effect of inter-atrial pacing intervals.
Sixteen of nineteen patients in our study derived benefit
from single-site pacing alone. Overall there was no differ-
ence in the effect of single-site atrial pacing from the RA
compared with pacing from the CS. However, subgroup
analysis showed that the greatest benefit from single-site
pacing occurred from the RAA.
The possible reasons for this are unclear, but the RAA
may represent the optimal single site for atrial resynchroni-
zation in this study. Previous work by Bennett (34) and
Katsivas et al. (35) has shown that RA septal pacing shows
benefit in patients with PAF, presumably for the same reason.
The greatest benefits in terms of reduction of episodes per
month of PAF in our study group were undoubtedly seen
during biatrial pacing, particularly utilizing the DCS. Al-
though RA plus PCS pacing showed an improvement in
episodes, the benefit did not reach statistical significance,
possibly because of the small numbers.
Atrial resynchronization is likely to have played an
important role. The benefit of coupling the RA with a
pacing site in the mid to distal coronary sinus supports
Daubert’s data (17–19). The explanation may be analogous
to optimizing depolarization in atrial defibrillation (36,37),
i.e., the capture and depolarization of the largest volume of
atrial myocardium within the smallest possible time. Vary-
ing the inter-atrial (RA–left atrial) pacing interval from 70
ms (“sequential”) to 16 ms (“simultaneous”) did not appear
to confer any further benefit.
Our results suggest that pacing rate as well as site
(anatomy) has a role in optimizing the clinical benefits of
biatrial pacing even in those without sinus bradycardia. This
adds weight to the theories that no single mechanism is
present in any one patient in at any time.
Study limitations. The study included a comparatively
small number of patients. However, all patients acted as
their own controls to allow comparison of multiple pacing
sites and intervals. An important limitation is the lack of
pacemaker event logs. Unfortunately, at the time of the
study, these had to be sacrificed for the customized gener-
ator software. Future pacing studies in patients with PAF
should include pacemaker Holter functions.
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The patients were not selected on the basis of their
inter-atrial conduction delay, although this may influence
outcome. Future studies are planned to include formal
measurements of this parameter.
Conclusions. We investigated the ability of single-site RA,
single-site CS, and biatrial pacing to prevent the recurrence
of AF in 19 patients with symptomatic drug-resistant PAF.
We have confirmed that the technique is safe in both the
long and short term and straightforward to perform. We
suggest that optimal benefits in selected patients are
achieved by combining an increase in the heart rate (in this
study 70 beats/min, although the effects of higher rates of
“overdrive” have yet to be established) with biatrial pacing.
The optimal site for the RA lead may be the RAA, whereas
the optimal CS site appears to be distal. Simultaneous
pacing appears to confer no benefits over sequential atrial
pacing. It is possible that optimal benefit in this group of
patients without underlying bradycardia may be obtained in
those with inter-atrial conduction delay.
Reprint requests and correspondence: Dr. Phyllis Holt, Dept.
of Cardiology, Maidstone Hospital, Hermitage Lane, Barming,
Kent ME16 9QQ, United Kingdom.
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